Compare Keel Infrastructure Corp. Common Stock (KEEL) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keel Infrastructure Corp. Common Stock vs Repligen Corporation Common Stock — how do they compare? Keel Infrastructure Corp. Common Stock trades at $2.48 (market cap $1.77B), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 6.3× Keel Infrastructure Corp. Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Keel Infrastructure Corp. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Keel Infrastructure Corp. Common Stock for 3 Days and Repligen Corporation Common Stock for 0 Days on average.
| KEEL | RGEN | |
|---|---|---|
Market Cap | $1.77B | $11.14B |
Volume | 34,111,650 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $6.66 | $194.57 |
52-Week Low | $1.71 | $102.87 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $2.09B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KEEL trades at $2.87, down 2.71% on the day, reflecting a bearish technical trend amid weak financial performance. The company reported a net loss of $208.51M on $229.28M revenue in 2025, with negative profit margins and cash flow from operations. Despite this, analyst consensus is unanimously bullish with a $6.25 price target, citing progress in its HPC and AI data center strategy, including a recent partnership with PowerSecure for its Moses Lake campus.
The outlook hinges on successful execution of its data center pivot, offering significant upside if leasing targets are met, but high execution risk and persistent losses pose substantial threats to shareholder value. Liquidity remains supported by financing activities, yet profitability challenges and competitive pressures require careful monitoring.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Keel Infrastructure Corp. Common Stock
Keel Infrastructure develops and owns digital and energy infrastructure for high-performance computing workloads. Its assets include data centers and power infrastructure that support AI computing.
Read more on KEEL →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
